The new drug, a genetically engineered version of a protein produced by human immune cells to combat infection, dramatically cut the expected number of deaths in a small group of seriously ill children. Researchers at the University of Texas in the United States said the results were far better than expected for such ill patients.
l A 20-year-old engineering student at the University of Sussex in Brighton is believed to have died from meningococcal meningitis. He is the second student to die of the disease in days. Earlier this week a first-year student at Portsmouth University died.Reuse content